Results 261 to 270 of about 51,741 (305)

Body composition measurement and diabetes - A new perspective on development of antibodies after SARS-CoV-2 booster vaccination. [PDF]

J Diabetes Metab Disord
Van Baal L, Tan S, Fuhrer D, Reinold J, Dittmer U, Fiedler M.   +5 more
europepmc   +1 more source

Zona ophtalmique après vaccination par Pfizer BNT162b2 et Moderna mRNA-1273 chez deux patients jeunes et immunocompétents

, 2022
M A Amblard, E Costantini, George Hayek, X Ricaud   +3 more
openalex   +2 more sources

Vaccine Platform-Dependent Differential Impact on Microbiome Diversity: Potential Advantages of Protein Subunit Vaccines. [PDF]

Vaccines (Basel)
Seong H, Yoon JG, Nham E, Choi YJ, Noh JY, Cheong HJ, Kim WJ, Lim S, Song JY.   +8 more
europepmc   +1 more source

Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study. [PDF]

PLoS Med
Kawamoto A, Hashida M, Ishida K, Furihata K, Ota A, Takahashi K, Sakakibara S, Nakano T, Takeshita F.   +8 more
europepmc   +1 more source

Primary and Booster COVID-19 Vaccination in Patients with Sjögren's Disease: Data from the Longitudinal SAFER Cohort Study. [PDF]

Vaccines (Basel)
Barbosa Beloni Lirio M, Machado KLLL, Assis Martins-Filho O, Miyamoto ST, Gurtler Pinheiro de Oliveira Y, Vieira Serrano É, Geraldo Mill J, Rosemarie Lallemand Tapia K, Baptista Ferreira L, Ribeiro de Oliveira J, Gouvea MDPG, Rodrigues Aguiar LG, Souza BO, Cruz VA, Xavier RM, Teixeira Carvalho A, de Souza VA, Ferreira GA, Monticielo OA, Neto ETDR, Sato EI, Pileggi GS, Valim V.   +22 more
europepmc   +1 more source

Cellular immune response to the anti-SARS-CoV-2 BNT162b2 mRNA vaccine in pediatric autoimmune inflammatory rheumatic disease patients and controls [PDF]

Tali Eviatar, A Pappo, Tal Freund, Yishai Friedlander, Ori Elkayam, David Hagin, Merav Heshin‐Bekenstein   +6 more
openalex   +1 more source

Autoantibody production in pregnancy: relationship with mRNA BNT162b2 immunization, active COVID-19, and pre-eclampsia. [PDF]

Front Immunol
da Silva MC, Diniz GTN, Correia MJDS, da Silva NCH, Barbosa CRM, Ferreira ALCG, de Melo MIB, de Magalhães JJF, Donadi EA, Souza AI, Lucena-Silva N.   +10 more
europepmc   +1 more source

A triple-blinded randomized control trial to evaluate the safety and immunogenicity of fractional doses of COVID-19 vaccines (ChAd0x1, AD26.COV2. S, and BNT162B2) among Nigeria adults: the SIFCoVAN trial. [PDF]

Trials
Musa AZ, Salako AO, Ayorinde JB, Ekama S, Odubela OO, Ige F, Idigbe IE, Ajibaye O, Odubela OR, Egharevba H, Ekpenyong M, Adeneye K, Folahanmi AT, Olojo II, Fowora MA, Okwuraiwe A, Elemuwa U, Ezenyi I, Fraden B, Oba A, Idris GA, Jimoh Y, Akande IR, Ogunwale J, Nwaiwu SO, Omale OL, Oyewunmi OO, Ezeanowi R, Agbabiaka A, Eyinade O, Osho A, Garba A, Yahya B, Musa BM, Ezejiofor O, Ejiro B, Iwalokun BA, Adigwe OP, Adeyeye MC, Faisal S, Ezechi OC, Salako BL.   +41 more
europepmc   +1 more source

Impaired SARS-CoV-2 vaccine responsiveness is not associated with subclinical atherosclerosis or cardiovascular disease. [PDF]

Eur Heart J Open
Andersson SHA, Chalou A, Mulholland M, Katra P, Ljungcrantz I, Andersson L, Engström G, Nilsson J, Schiopu A, Björkbacka H, Engelbertsen D.   +10 more
europepmc   +1 more source

The emerging role of the gut microbiota in vaccination responses. [PDF]

Gut Microbes
Decker V, Qureshi K, Roberts L, Powell N, Marchesi JR, Mullish BH, Alexander JL.   +6 more
europepmc   +1 more source